Founded in 2010 by four individuals with scientific and business expertise, Orega Biotech is a French biotech company that specializes in developing monoclonal antibodies for cancer immunotherapy. Their target discovery program focuses on discovering and validating novel cancer targets in the tumor microenvironment. Orega Biotech's lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate Pharma and partnered with AstraZeneca, with its progression in phase 2 clinical trial announced in 2022. The company's second program, at the preclinical stage, targets a new regulator of the immune response to overcome resistance to anti-PD1 antibodies. The company's investors include initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création, and INSERM-Transfert Initiative.